Racial and ethnic disparities and implications for the prevention of HIV among persons who inject drugs

Current Opinion in HIV and AIDS

Volumn 7, Issue 4, 2012, Pages 354-361

  Jarlais, Don C D ^a   Cooper, Hannah L F ^b   Bramson, Heidi ^a   Deren, Sherry ^c   Hatzakis, Angelos ^d   Hagan, Holly ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

epidemiology; ethnic minority; global health; HIV; injecting drug use; people who inject drugs; policy; prevention; racial minority injection drug use

Indexed keywords

AMPHETAMINE; CODEINE; DIAMORPHINE; FENTANYL; HYDROCODONE; MORPHINE; OPIATE; OXYCODONE;

AFRICA; AUSTRALIA; BRAZIL; CANADA; COST OF ILLNESS; DRUG ABUSE; EPIDEMIC; ETHNIC DIFFERENCE; EUROPE; GOVERNMENT; GREECE; HEALTH CARE POLICY; HEALTH DISPARITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; INJECTION DRUG USER; MALAYSIA; NETHERLANDS; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RUSSIAN FEDERATION; SEXUAL TRANSMISSION; SOUTHEAST ASIA; SPAIN; UNITED STATES; VIRUS TRANSMISSION;

COMMUNICABLE DISEASE CONTROL; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HIV INFECTIONS; HUMANS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84862520908     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328353d990     Document Type: Review

References (48)

1. Mathers B, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372:1733-1745
2. Musto D. The American Disease: Origins of Narcotic Control. New Haven, CT: Yale University Press; 1973
3. Aceijas C, Stimson G, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004; 18:2295-2303 (Pubitemid 39620222)
4. Mathers B, Cook C, Degenhardt L. Improving the data to strengthen the global response to HIV among people who inject drugs. Int J Drug Policy 2010; 21:100-102
5. Reid S. Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review. Harm Reduct J 2009; 24:6
6. & Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012.
7. Santos GM, Das M, Colfax GN. Interventions for noninjection substance use among US men who have sex with men: what is needed. AIDS Behav 2011; 15:S51-S56.
8. Des Jarlais DC, Arasteh K, Perlis T, et al. The transition from injection to noninjection drug use: long-term outcomes among heroin and cocaine users in New York City. Addiction 2007; 102:778-785 (Pubitemid 46633361)
9. de la Fuente L, Barrio G, Royuela L, Bravo MJ, The Spanish Group for the Study of the Route of Heroin Administration. The transition from injecting to smoking heroin in three Spanish cities. Addiction 1997; 92:1749-1763 (Pubitemid 28006043)
10. van Ameijden E, Coutinho RA. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Com Health 2001; 55:356-363 (Pubitemid 32336982)
11. Bastos FI, Caceres C, Galvao J. AIDS in Latin America: assessing the current status of the epidemic and the ongoing response. Int J Epidemiol 2008; 37:729-737
12. Tejani E, Chawarski M, Mazlan M, Schottenfeld RS. Proceedings of the temporal changes in initiation of injection use in heroin users in Malaysia 1968 to 2009. Presented at the College on Problems of Drug Dependence, 18-23 June 2011; Hollywood, FL; 2011
13. Des Jarlais D, H agan H, Friedman S, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995; 274:1226-1231
14. Malliori M, Terzidou M, Paraskevis D, Hatzakis A. HIV/AIDS among IDUs in Greece: Report from a recent outbreak and initial response policies. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2011
15. Paraskevis D, Hatzakis A. An ongoing HIV outbreak among intravenous drug users in Greece: Preliminary summary of surveillance and molecular epidemiology data. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2011. Epidemiological data on recent HIV outbreak among injectors in Greece.
16. Paraskevis D, Nikolopoulos G, Tsiara C, et al. HIV-1 outbreak among injecting drug users in Greece, 2001: a preliminary report. Euro Surveill 2011; 16:36. Information on the HIV outbreak in Greece.
17. Pharris A, Wiessing L, Sfetcu O, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania. Euro Surveill 2011; 16:48.
18. Wiessing L, Likatavicius G, Hedrich D, et al. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011; 16:48
19. Des Jarlais D, Feelemyer J, Modi S, et al. Transitions from injection-drug-useconcentrated to self-sustaining heterosexual HIV epidemics: a systematic review. PLoS One 2012; 7:e31227
20. Hong Y, Li X. HIV/AIDS behavioral interventions in China: a literature review and recommendation for future researC.H. AIDS Behav 2009; 13:603-613
21. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
22. Cooper HL, Des Jarlais DC, Ross Z, et al. Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors use of sterile syringes. Am J Public Health 2011; 101:1118-1125
23. Rockwell R. Injection drug users, sexual partners and urban geography: convenience and equity issues in a pharmacy-based sterile syringe accessed program. Humanity Society 2005; 29:55-70
24. Williams C, Metzger D. Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health 2010; 100:1068-1074
25. Cooper H, Des Jarlais DC, Ross Z, et al. Spatial access to sterile syringes and the odds of injecting with an unsterile syringe among injectors: A longitudinal multilevel study. J Urban Health (in press).
26. Cooper HL, Des Jarlais DC, Tempalski B, et al. Drug-related arrest rates and spatial access to syringe exchange programs in New York City health districts: combined effects on the risk of injection-related infections among injectors. Health Place 2012; 18:218-228
27. Bluthenthal R, Kral A, Lorvick J, Watters J. Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Med Anthropol 1997; 18:61-83 (Pubitemid 127822119)
28. Bluthenthal RN, Lovrick J, Kral A, et al. Collateral damage in the war on drugs: HIV risk behaviors among injection drug users. Int J Drug Policy 1999; 10:25-38 (Pubitemid 29251553)
29. Maher L, Dixon D. Policing and public health: law enforcement and harm minimization in a street-level drug market. Brit J Criminol 1999; 39:88-512
30. Wood E, Kerr T, Small W, et al. The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr 2003; 34:116-118 (Pubitemid 37100123)
31. Garrett L. Laurie Garrett Web Page, 2012. http://www.lauriegarrett.com/ index.php/en/home/2581. [Accessed 13 February 2012]
32. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DC, et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Soc Sci Med 2009; 68:579-590
33. Brown C. How Punitive Drug Policy Fuels the HIV Epidemic in Russia. 2011. http://blog.soros.org. Blog New York, Open Society Foundations. [Accessed 13 February 2012]
34. Finnerty E. Opiate substitution treatment in the former Soviet Union. Lancet 2006; 368:1066 (Pubitemid 44402678)
35. Parfitt T. Vladimir Mendelevich: fighting for drug substitution treatment. Lancet 2006; 368:279 (Pubitemid 44067233)
36. Wood E, Werb D, Kazatchkine M, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet 2010; 376:310-312
37. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-583
38. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168:1099-1109
39. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204:74-83
40. Turner KM, Hutchinson S, Vickerman P. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106:1978-1988
41. United States Federal Drug Administration (FDA). Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV), 2012. http://www. fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm 256328.htm. [Accessed 13 February 2012] New highly effective treatment for type 1 hepatitis C.
42. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237-S244 (Pubitemid 35253486)
43. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaive patients with genotype 1 hepatitis C infection (SPRINT-1): an openlabel, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716
44. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965 (Pubitemid 32913521)
45. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838
46. Colvin, HM, Mitchell, AE (Eds). Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: Institute of Medicine of the National Academies; 2010
47. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2010; 18:364-373 (Pubitemid 47376916)
48. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77:81-86. (Pubitemid 39656102)